{"entity":{"id":"nct05684965","kind":"trial","name":"XTX301 in Patients With Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of XTX301 in advanced solid tumours, run by Xilio Development, Inc., now recruiting.","summary":"XTX301 in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05684965 by Xilio Development, Inc., with 358 participants planned, started 2023-05-11 and due to reach its primary completion in 2028-09. Interventions recorded: XTX301.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05684965","url":"https://clinicaltrials.gov/study/NCT05684965"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["xilio-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05684965","phase":"1/2","setting":"A First-in-Human, Multicenter, Phase 1/2, Open-Label Study of XTX301 in Patients With Advanced Solid Tumors","sponsor":"Xilio Development, Inc.","enrolled":358,"outcomes":[]},"route":"/trials/nct05684965/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"company":[{"id":"xilio-therapeutics","kind":"company","name":"Xilio Therapeutics","route":"/companies/xilio-therapeutics/"}]}}